Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis

Clinical Respiratory Journal

Volumn 10, Issue 6, 2016, Pages 731-739

  Yang, Jia Wei ^a,b   Fan, Li Chao ^a   Lu, Hai Wen ^a   Miao, Xia Yi ^a   Mao, Bei ^a,b   Xu, Jin Fu ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

bronchiectasis; efficacy; inhaled antibiotic; meta analysis; safety

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL COLONIZATION; BRONCHIECTASIS; BRONCHOSPASM; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HEADACHE; HEMOPTYSIS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NONCYSTIC FIBROSIS BRONCHIECTASIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; SPUTUM ANALYSIS; TASTE DISORDER; WHEEZING; DRUG ADMINISTRATION; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPUTUM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPUTUM; TREATMENT OUTCOME;

EID: 84923673670     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12278     Document Type: Article

References (41)

1. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006;100: 2183–2189.
2. Martínez-García MA, Perpiná-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128: 739–745.
3. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188: 647–656.
4. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65: i1–58.
5. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57: 15–19.
6. Martínez-García MA, Soler-Cataluna JJ, Perpiná-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132: 1565–1572.
7. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. an international derivation and validation study. Am J Respir Crit Care Med. 2014;189: 576–585.
8. Antoniu SA, Trofor AC. Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. Expert Opin Pharmacother. 2011;12: 1191–1194.
9. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186: 657–665.
10. Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J. 2009;33: 171–181.
11. Cameron EJ, McSharry C, Chaudhuri R, Farrow S, Thomson NC. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy. 2012;42: 1302–1312.
12. Li H, Liu DH, Chen LL, et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother. 2014;58: 511–517.
13. Chan GL. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. DICP. 1989;23: 788–794.
14. Crowther Labiris NR, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis: a pilot study. Am J Respir Crit Care Med. 1999;160: 1711–1716.
15. Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv. 2006;3: 71–86.
16. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2008;21: 71–76.
17. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172: 137–159.
18. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med. 1999;93: 476–480.
19. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162: 481–485.
20. Couch LA. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest. 2001;120: 114S–117.
21. Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother. 2005;39: 39–44.
22. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006;130: 1503–1510.
23. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183: 491–499.
24. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz P, Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013;41: 1107–1115.
25. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gondal I. ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68: 812–817.
26. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189: 975–982.
27. Wilson CB, Jones PW, O'leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997;10: 1754–1760.
28. O'Donnell AE. Antimicrobial therapy for bronchiectasis. Clin Chest Med. 2012;33: 381–386.
29. Antonela Antoniu S. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa. Expert Rev Anti Infect Ther. 2012;10: 1439–1446.
30. Justo JA, Danziger LH, Gotfried MH. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis. 2013;7: 272–287.
31. Hill AT, Campbell EJ, Hill SL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000;109: 288–295.
32. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharaligam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med. 2012;106: 356–360.
33. Lin HC, Cheng HF, Wang CH, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med. 1997;155: 2024–2029.
34. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005;127: 1420–1426.
35. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11: 425–434.
36. Farber JE, Ross J. The use of aerosol penicillin and streptomycin in bronchopulmonary infections. Calif Med. 1950;73: 214–217.
37. Stockley RA, Hill SL, Burnett D. Nebulized amoxicillin in chronic purulent bronchiectasis. Clin Ther. 1984;7: 593–599.
38. Hill SL, Morrison HM, Burnett D, Stockley RA. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax. 1986;41: 559–565.
39. El-Din MAT, Palmer LB, El-Tayeb MN, Khalil I, Gabr MS. Nebulizer therapy with antibiotics in chronic suppurative lung disease. J Aerosol Med. 1994;7: 345–350.
40. Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J. 2007;37: 495–498.
41. Berlana D, Llop JM, Manresa F, Jodar R. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Pharmacotherapy. 2011;31: 146–157.